
==== Front
Infect Dis Rep
Infect Dis Rep
idr
Infectious Disease Reports
2036-7430
2036-7449
MDPI

10.3390/idr16050066
idr-16-00066
Review
Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review
https://orcid.org/0009-0003-2452-4407
Paternò Raddusa Michele Salvatore 1
https://orcid.org/0000-0002-5650-6911
Marino Andrea 2*
https://orcid.org/0000-0002-6919-1955
Celesia Benedetto Maurizio 2
Spampinato Serena 1
Giarratana Carmen 1
Venanzi Rullo Emmanuele 1
Cacopardo Bruno 2
https://orcid.org/0000-0002-8113-8452
Nunnari Giuseppe 2
Petrosillo Nicola Academic Editor
1 Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy; michelepat93@gmail.com (M.S.P.R.); serenaspampinato93@gmail.com (S.S.); carmengiarratana15@gmail.com (C.G.); emmanuele.venanzirullo@unime.it (E.V.R.)
2 Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy; bmcelesia@gmail.com (B.M.C.); cacopard@unict.it (B.C.); giuseppe.nunnari1@unict.it (G.N.)
* Correspondence: andrea.marino@unict.it
01 9 2024
10 2024
16 5 846863
19 5 2024
27 8 2024
27 8 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
The intersection of Human Immunodeficiency Virus (HIV) infection and cardiovascular disease (CVD) represents a significant area of concern; advancements in antiretroviral therapy (ART) have notably extended the life expectancy of people living with HIV (PLWH), concurrently elevating the prevalence of chronic conditions such as CVD. This paper explores the multifaceted relationship between HIV infection, ART, and cardiovascular health, focusing on the mechanisms by which HIV and ART contribute to increased cardiovascular risk, including the promotion of endothelial dysfunction, inflammation, immune activation, and metabolic disturbances. We highlight the critical roles of HIV-associated proteins—Tat, Nef, and gp120—in accelerating atherosclerosis through direct and indirect pathways that exacerbate endothelial damage and inflammation. Additionally, we address the persistent challenge of chronic inflammation and immune activation in PLWH, factors that are strongly predictive of non-AIDS-related diseases, including CVD, even in the context of effective viral suppression. The impact of ART on cardiovascular risk is examined, with particular attention to the metabolic implications of specific ART regimens, which can influence lipid profiles and body composition, thereby modifying CVD risk. The therapeutic potential of statins, aspirin, and emerging treatments such as PCSK9 inhibitors in mitigating cardiovascular morbidity and mortality among PLWH is discussed, alongside considerations for their use in conjunction with ART. Our review underscores the necessity for a comprehensive, multidisciplinary approach to cardiovascular care in PLWH, which integrates vigilant cardiovascular risk assessment and management with HIV treatment. As we navigate the evolving landscape of HIV care, the goal remains to optimize treatment outcomes while minimizing cardiovascular risk, ensuring that the gains in longevity afforded by ART translate into improved overall health and quality of life for PLWH.

HIV
HIV and cardiovascular diseases
AIDS
HIV comorbidities
non-AIDS-related comorbidities
This research received no external funding.
==== Body
pmc1. Introduction

In 2022, an estimated 39 million people worldwide (ranging from 33.1 million to 45.7 million) were living with HIV. Among them, 86% (varying from 73% to over 98%) were aware of their HIV status, 76% (between 65% and 89%) were receiving antiretroviral therapy (ART), and 71% (from 60% to 83%) had achieved viral suppression [1].

Due to the effectiveness of ART, the mortality rate among people living with HIV (PLWH) has decreased, leading to a significant increase in their life expectancy by more than 50 years [2,3,4,5,6]. At the same time, a global rise in chronic diseases such as cardiovascular disease (CVD) has been observed within this population [7]. PLWH face higher rates of CVD risk factors compared to the general population, including dyslipidemia, diabetes, metabolic syndrome, smoking, hypertension, and drug use. Additionally, HIV-specific factors like ART, chronic inflammation, and immune activation also contribute to the increased risk of CVD [8]. Hypertension affects 21.2% of HIV-positive individuals versus 15.9% of HIV-negative individuals, while dyslipidemia is present in 23.3% of HIV-positive compared to 17.6% of HIV-negative patients [9].

A meta-analysis and systematic review found that HIV-positive individuals have a 1.5 to 2 times higher risk of MI compared to their HIV-negative counterparts [10,11]. A study reported MI rates of 11.13 per 1000 person-years in HIV-positive patients versus 6.98 in HIV-negative patients, even after adjusting for confounding factors like age, sex, and traditional cardiovascular risk factors [12].

Atherosclerosis, a chronic inflammatory condition of the arterial wall, is the major precursor of CVD, leading to severe outcomes. Advanced stages of atherosclerosis are characterized by damage to the intimal-media layer of the arterial wall and the buildup of plaques. These plaques can erode or rupture, leading to thrombotic events with potentially fatal consequences, like myocardial infarction and stroke. The development of atherosclerosis involves a complex interplay of factors, from lipid accumulation to chronic inflammation within the arterial wall [13]. As shown by several studies involving coronary CT angiography, PLWH are more likely either to have coronary artery plaque than those without HIV or to have a greater extent of non-calcified plaque, which is particularly prone to rupture [14,15]. All this evidence highlights a critical need for ongoing monitoring and tailored interventions to manage cardiovascular health in HIV-positive populations.

2. HIV-Mediated Molecular Mechanisms

Peripheral artery disease (PAD) is notably more prevalent among PLWH than in the general population, serving as a common clinical manifestation of atherosclerosis and signaling an increased risk of cardiovascular events such as myocardial infarction (MI) and stroke. Its prevalence in PLWH is 20.7%, compared to just 1% in those not infected [16,17]. InResearch suggests that HIV-associated proteins, including Tat, Nef, and gp120, play significant roles in the onset and acceleration of atherosclerosis. These proteins induce endothelial dysfunction through various pathways.

Gp120 is part of the envelope protein complex of HIV. It binds to the CD4 receptor on the surface of host T cells and other immune cells, being the first step in the fusion process of the viral membrane with the host cell membrane, leading to viral entry into the host cell.

Specifically, HIV gp120 protein disrupts normal endothelial cell function, damaging proteins that maintain cell junctions, increasing blood vessel permeability, and triggering a chain of pathological changes in vascular tissue. These changes can advance stromal degeneration, necrosis, sclerosis, and hyalinosis, potentially leading to various complications, including cardiovascular issues [18,19].

Gp120’s toxic effects on endothelial cells are mediated by activation of caspase-3, involved in apoptosis; activation of Bax, regulating apoptosis; involvement of protein kinase C (PKC) in cellular signaling; activation of mitogen-activated protein kinase p38 (MAPK), affecting cellular processes; and direct interaction with the CXCR4 co-receptor, affecting immune response and cell adhesion [18].

Moreover, gp120 activates the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), leading to reactive oxygen species (ROS) production, nuclear factor-kappa B (NF-kB) activation, and increased levels of pro-inflammatory factors, contributing to vascular remodeling and enhancing plaque vulnerability [20,21].

Tat protein promotes viral transcription by enhancing the elongation of RNA transcripts from the HIV long terminal repeat (LTR), which is critical for the production of new viral particles.

Tat protein inducts the release of proinflammatory cytokines, concurrently prompting the endothelial expression of IL-1b, MCP-1, vascular cell adhesion protein 1 (VCAM-1), and E-selectin through the NF-kB-dependent pathway [22]. Furthermore, Tat induces oxidative stress and a mild inflammatory response in the endothelium by activating NADPH oxidase [22]. Tat protein stimulates production of IFN-γ, TNF-α, IL-6, and IL-17 and the apoptosis of endothelial cells; this causes atherosclerotic lesions due to an easier accumulation of low-density lipoprotein due to sub-endothelial space enhanced permeability [23].

The Nef protein is involved in downregulating the expression of certain cell surface receptors (such as CD4 and MHC I) on infected cells, helping HIV to evade the host immune system.

Nef protein amplifies the adherence of T-lymphocytes to endothelial cells, impeding their diapedesis and migration into the subendothelial space, potentially in association with the activity of matrix metalloproteinases (MMPs) [19,24]. Nef’s role extends to the alteration of cholesterol homeostasis in endothelial cells through the phosphorylation of caveolin-1, disrupting high-density lipoprotein (HDL)-mediated cholesterol efflux and promoting the formation of foam cells [24].

Additionally, Nef interferes with the normal function of the ATP-binding cassette transporter A1 (ATP-BC A1), hindering cholesterol efflux from infected macrophages and fostering foam cell development [25] (Figure 1).

Moreover, HIV ribonucleic acids bind to Toll-like receptor 8 (TLR-8), facilitating the transformation of monocytes/macrophages into foam cells within the vascular wall in a dose-dependent manner. This mechanism further highlights the complex interaction between HIV infection and cardiovascular disease, emphasizing the multifaceted impact of HIV on vascular health and disease progression in PLWH [26].

3. Role of Chronic Inflammation and Immune Activation

3.1. Inflammatory Markers and Immune Activation

PLWH are characterized by noticeable abnormal inflammation and immune activation, which are considered strong predictive indicators of mortality and non-AIDS diseases developing, such as CVD [27,28,29,30,31].

Chronic inflammation in PLWH is marked by elevated levels of pro-inflammatory cytokines, including IL-6, IL-1β, TNF-α, VCAM-1, ICAM-1, CRP, and D-dimer [32]. These inflammatory markers remain elevated compared to the general population even after achieving viral suppression through ART [33]. This persistent inflammation contributes significantly to the increased cardiovascular risk in PLWH.

3.2. Demographic Influences on Inflammation and CVD

Additionally, demographic factors such as age, gender, and race significantly influence the progression of cardiovascular diseases in this population. Studies have shown that older age is associated with higher levels of inflammation and a greater burden of atherosclerosis in PLWH [34]. Similarly, men with HIV are at a higher risk of developing cardiovascular diseases compared to women, partly due to differences in inflammation and immune activation [35]. Racial disparities also play a crucial role; for example, African Americans living with HIV tend to have higher levels of inflammatory markers and a greater prevalence of cardiovascular diseases compared to their Caucasian counterparts [36].

The interplay between chronic inflammation, immune activation, and these demographic factors necessitates a comprehensive approach to understanding and managing cardiovascular risks in PLWH. Addressing these risks requires not only effective viral suppression but also targeted interventions to reduce inflammation and improve cardiovascular health outcomes. Strategies such as the use of anti-inflammatory medications and lifestyle modifications, including diet and exercise, may be beneficial in this regard [37].

3.3. Gut Microbiota and Systemic Inflammation

Gut microbiota dysbiosis and increased gut permeability are significant contributors to systemic inflammation in PLWH, driven by HIV’s disruption of gut homeostasis through targeting mucosal CD4+ T cells. This disruption leads to epithelial cell death, diminished cell–cell adhesion, and microbial translocation, where products like lipopolysaccharide (LPS) enter the bloodstream, exacerbating immune activation and chronic inflammation [37,38,39]. This population exhibits elevated levels of inflammation markers, including IL-6, IL-1β, TNF-α, VCAM-1, ICAM-1, CRP, and D-dimer, many of which remain elevated even after viral suppression [23,32,33]. The imbalance in the gut microbiota is closely linked to the onset and progression of various diseases, including cardiovascular diseases and immune disorders, through alterations in gut permeability and subsequent movement of pathogens into the bloodstream [40,41]. These alterations activate pathways like TLR4, further increasing cytokine production and pro-inflammatory factors [38,42,43]. Restoring gut microbiota balance with probiotics or prebiotics may help manage this chronic inflammation in PLWH.

3.4. Role of Activated T Cells and Monocytes

Activated T cells and monocytes play a role in sustaining inflammation, hypercoagulation, and endothelial dysfunction, all pivotal in the progression of cardiovascular disease [24,44]. Monocytes maintain the HIV reservoir among individuals who have achieved virological suppression, contributing to persistent immune activation and inflammation. The activation of monocytes persists even following the initiation of treatment, with a noted correlation between the thickness of the carotid intima-media and the expression of surface markers/receptors CD11b and C-X3-C motif receptor-1 (CX3CR1) on activated monocytes [43].

Elevated levels of soluble CD163 (sCD163), an endocytic receptor for haptoglobin-hemoglobin complexes, have been associated with non-calcified coronary plaques and arterial inflammation in individuals living with HIV [45]. IL-6 stimulates the conversion of monocytes into activated macrophages via the macrophage colony-stimulating factor (M-CSF). Foam cells, which are heterogeneous macrophages filled with cholesterol, form the basic building blocks of arterial lesions caused by atherosclerosis. Their accumulation results in fatty patches that eventually become plaques, playing a direct role in the development of atheroma [46].

Lipid accumulation in dendritic or macrophage cells triggers the activation of the inflammasome, including NLRP3, which is crucial in the pathophysiology of HIV-induced inflammation and plays a role in the initiation and progression of atherosclerosis [47,48].

3.5. MAP-Kinase Signaling and HIV-Related Inflammation

The replication of HIV-1 can be favorably regulated by the MAP-kinase signal loop, with ERKs, p38 MAP-kinases, and cJun NH2-terminal kinases (JNK) linked to HIV-related inflammation and the promotion of atherosclerosis through various mechanisms, including the activation of NF-kB and the promotion of ICAM-1 expression, VEGF-induced endothelial cell permeability, and the development of reactive myocardial fibrosis [49,50,51,52].

MAP-kinase and NF-kB disruptions, therefore, have a dual function in HIV-induced inflammation and vascular lesions associated with atherosclerosis.

3.6. Perivascular Adipose Tissue and HIV-Related Atherosclerosis

The function of perivascular adipose tissue (PVAT) in the context of low-grade inflammation and the development of CVD among PLWH is significant. Proinflammatory adipokines and cytokines produced by PVAT’s defective phenotype diffuse through the vascular wall or the vasa vasorum [53]. Remarkably, the release of anti-inflammatory cytokines, particularly IL-6 and IL-10, is also a hallmark of HIV-associated inflammation. This results in a destabilized PVAT phenotype due to the overproduction of hematogenous CD163+ macrophages and insulin resistance [54]. CD163+ macrophages are associated with increased angiogenesis, microvascular permeability, and endothelial inflammation of the plaque wall. They also lead to the loss of VE-cadherin by overproduction of VEGF-A, altering the morphology and integrity of endothelial cells [55]. Morphologic variations exist between “ordinary” atherosclerosis and HIV-related atherosclerosis. Intravascular ultrasound showed that those living with HIV had greater rates of hypoechoic plaques and lower plaque burdens [56]. In a multicenter study conducted by Wendy S. et al. using computed tomographic angiography on 1001 individuals (618 HIV-infected and 383 uninfected men who have sex with men), it emerged that noncalcified plaque is more common and prominent in PLWH than in the control group [14]. Increased carotid IMT has been observed in the setting of HIV in numerous investigations. This has been linked with higher mortality and inflammatory marker levels [34,57]. In a cross-sectional study of 81 participants, it was shown that people living with HIV have elevated levels of arterial inflammation than group control, as determined by fluorodeoxyglucose-positron emission tomography/computed tomography; this is associated with macrophage activity producers [58].

4. Metabolic Impairment in PLWH

Individuals with untreated HIV infection exhibit a higher prevalence of cardiovascular abnormalities compared to the general population, with endothelial dysfunction and carotid intima-media thickening being especially prominent. Dyslipidemia, insulin resistance, and changes in body composition are highly prevalent among PLWH and are significant contributors to the elevated risk of CVD observed in this population [59].

The study by Masenga et al. [60] emphasizes that the prevalence of hypertension and metabolic syndrome is higher in HIV-positive individuals, partly due to impaired glucose metabolism and increased insulin resistance. These findings are supported by Aurpibul et al. [61], who report that perinatally infected youth on ART also exhibit significant metabolic syndrome markers, indicating that metabolic complications begin early in the HIV-positive population.

In the absence of ART, HIV infection leads to significant reductions in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). These lipid abnormalities become more pronounced as HIV progresses, with individuals at advanced stages, such as AIDS, exhibiting the most severe metabolic impairments [23,45,59,62]. Specifically, those with AIDS have notably higher levels of triglycerides compared to individuals with HIV but without AIDS and the general population. These patterns of lipid dysregulation mirror those observed in other states of chronic infection and inflammation. Consistent findings across different studies indicate that these lipid abnormalities contribute to the heightened cardiovascular risk seen at various stages of HIV infection [45].

PLWH have higher concentrations of leptin and lower levels of adiponectin; these imbalances can lead to increased central fat mass, worsened insulin sensitivity, higher glucose concentrations, and an elevated risk of cardiovascular disease [44].

HIV infection frequently results in changes to body composition. Patients who were first diagnosed during the ART era often experienced an increase in visceral fat around the abdomen and a reduction in subcutaneous fat. The changes in fat distribution have been varied and associated with the accumulation of ectopic adipose tissue in the muscle and liver, as well as with insulin resistance. These alterations are attributable to several factors, including the effects of ART itself. The use of specific thymidine NRTIs has been linked to the deposition of ectopic adipose tissue in the muscle and liver, loss of subcutaneous fat, and vascular inflammation [63].

With the initiation of ART, elevations in both visceral and subcutaneous fat are commonly observed due to more effective treatment options, and rates of generalized obesity are increasing among PLWH, regardless of region [62]. Changes in body composition, including the accumulation of extra-visceral adipose tissue, have been associated with overall mortality. Furthermore, these changes have been linked to an increase in the quantity of both calcified and noncalcified coronary plaques, highlighting the complex interplay between HIV infection, ART, and cardiovascular risk [64].

5. Role of Co-Infections

Co-infections significantly influence the development and exacerbation of atherosclerosis in HIV-infected individuals by amplifying the risk factors associated with cardiovascular diseases. The persistent inflammation observed in HIV-infected patients is further sustained by co-infections with other viruses, such as hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein–Barr virus (EBV). Studies, including those by Márquez et al., indicate that HIV/HCV co-infected patients exhibit higher levels of inflammatory markers such as sCD14 and IL-6 compared to those with chronic hepatitis or HIV mono-infection. Elevated levels of pro-inflammatory and profibrogenic chemokines such as MCP-1 and eotaxin have been linked to HIV/HCV co-infection, suggesting a heightened proinflammatory response. This is compounded by the increased risk of metabolic disorders in HIV/HCV co-infected individuals, further elevating their risk for cardiovascular diseases due to enhanced endothelial dysfunction and chronic inflammation. The evidence underscores the need for comprehensive management strategies that address not only HIV but also co-infections to mitigate the increased risk of cardiovascular diseases, including atherosclerosis, in this population [65,66].

Furthermore, co-infections like CMV can damage epithelial connections, leading to bacterial translocation and persistent gastrointestinal inflammation, which can draw HIV-target cells to the site, promoting HIV persistence. CMV also enhances HIV persistence by promoting the survival of HIV-infected cells, stimulating inhibitory immune pathways, and directly transactivating latent HIV. The association of higher levels of sCD14, CXCL10, and genetically intact HIV in individuals co-infected with HIV and HBV underlines the impact of immune activation on the persistence and complexity of HIV infection [67,68,69,70].

6. Role of ART

6.1. Impact on Life Expectancy and Cardiovascular Risks

The life expectancy of PLWH has significantly increased because of the efficiency of ART, which has also reduced the death rate among PLWH [71].

The literature suggests that certain ART regimens may play a role in stimulating endothelial dysfunction and promoting atherosclerosis. HIV, the immune reconstitution response, and antiretroviral therapy may provoke early endothelial activation, potentially making them pro-atherogenic factors [72,73].

Conversely, antiretroviral therapy is beneficial in mitigating the proinflammatory impact of HIV infection. Post-treatment, PLWH exhibits a significant decline in the concentrations of IL-6, IL-1β, D-dimer, ICAM-1, VCAM-1, and TNF-α during ART.

6.2. Insights from Clinical Studies: SMART and START

The “Strategies for Management of Antiretroviral Therapy” (SMART) and the “Strategic Timing of Antiretroviral Treatment” (START) studies have provided valuable insights into antiretroviral therapy and its optimal timing in relation to HIV infection and CVD. The SMART study showed that continuous ART use in individuals with a CD4+ cell count below 350/µL resulted in a decrease in AIDS-related complications and occurrences of CVD. Those who delayed or interrupted treatment faced a higher risk of cardiovascular disease. The START study found that immediate ART administration led to a 40% reduction in AIDS-related cases, although it did not significantly impact the occurrence of CVD [74].

Both the SMART and START studies support the notion that antiretroviral therapy should decrease the frequency of CVD, but ART alone may not suffice as a preventive measure against cardiovascular events in individuals with HIV.

6.3. Dyslipidemia and ART Regimens

Dyslipidemia is a primary risk factor for cardiovascular disease and atherosclerosis. Byonanebye et al.’s study from the International Cohort Consortium of Infectious Disease (RESPOND) in 2021 found that patients, both ART-naïve and ART-experienced, treated with Integrase Strand Transfer Inhibitor (INSTI)-based therapy were less likely to experience dyslipidemia compared to those treated with protease inhibitor (PI)-based therapy [75].

PIs have been associated with an increase in hypertriglyceridemia and levels of total and LDL cholesterol [76]; ritonavir, in particular, has been linked to hyperlipidemia and demonstrated to increase cardiovascular mortality, risk of myocardial infarction, and have a minor but statistically significant impact on the progression of carotid-wall thickness [77,78].

Furthermore, ritonavir-boosted darunavir use was associated with an increased risk of CVD [79].

Reductions in adiposity and leptin secretion lead to decreased endothelial leptin signaling, subsequently reducing NO bioavailability mediated by CCR5 and NADPH oxidase 1, directly causing ritonavir-associated endothelial dysfunction [78].

Although newer PIs have less severe metabolic side effects, PLWH with dyslipidemia should be treated with consideration for the impact of these drugs on lipids [51]. Moreover, a connection between PI treatment and increased intima–media thickness (IMT) comparing Doppler data has been shown [80].

First-line HIV treatment guidelines no longer include boosted atazanavir and darunavir; however, darunavir is used as salvage therapy, part of two-drug regimens, or as alternatives for first-, second-, and third-line regimens. Finally, considering the baseline risk for cardiovascular disease is advisable before using a PI-based regimen, especially in the elderly PLWH [81,82].

Currently, INSTIs are the cornerstone of antiretroviral therapy. INSTIs are superior to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and PIs regarding virological efficacy, tolerability, and the risk of drug–drug interactions [83,84].

Weight gain has been linked to INSTI-based ART in both treatment-naïve and treatment-experienced individuals [85,86]; those newly starting INSTI-based ART have reported an elevated incidence of arterial hypertension and diabetes [87,88].

6.4. Considerations for Switching ART Regimens

The “Surveillance Cohort Long-Term Toxicity Antiretrovirals” (SCOLTA), an observational cohort trial involving PLWH treated with efavirenz or a ritonavir-boosted PI-based regimen, switching to dolutegravir, elvitegravir, or rilpivirine, observed a decrease in LDL-C among patients who transitioned from a ritonavir-boosted PI to elvitegravir. Additionally, a reduction in total cholesterol was noted across all groups except for the efavirenz to elvitegravir switch group upon transitioning to an INSTI-based regimen. However, no appreciable change in triglycerides was observed among those who switched to an INSTI-based regimen, emphasizing the nuanced impacts of different ART regimens on lipid profiles [89].

According to recent antiretroviral treatment guidelines, regimens based on tenofovir, a nucleoside reverse transcriptase inhibitor (NRTI), are among the first-line therapies recommended for most PLWH. Treatments based on tenofovir disoproxil fumarate (TDF) have been associated with higher plasma levels of tenofovir, with potential adverse effects on kidney and bone. Regimens based on tenofovir alafenamide (TAF) result in fewer negative effects and achieve higher intracellular levels of tenofovir-diphosphate than TDF, albeit with lower plasma levels of tenofovir. On the contrary, TDF exhibits a “statin-like” effect due to indirect mechanisms on lipid metabolism, adipose tissue, and liver function, whereas TAF showed a “neutral” effect on lipid assessment. According to that, switching from TDF to TAF could result in higher levels of total cholesterol due to the end of the TDF-statin effect [90,91]. In addition, TAF, compared to TDF, is associated with greater weight gain, both after the switch and in treatment-naïve patients [92,93]. According to Gregory D. Huhn et al., lipid changes with TAF as part of co-formulated regimens do not significantly alter CVD risk profiles compared to TDF [94].

NNRTIs have varying effects on lipids. Etravirine had a neutral effect on TC, LDL-C, and TG. Compared to nevirapine and rilpivirine, efavirenz raises TG and LDL-C more than the others [95].

Switching from a nevirapine-based ART to a rilpivirine-based ART resulted in a mean decrease in LDL-C and total cholesterol [96]. Doravirine (DOR) appears to be well tolerated in both naïve and experienced PLWH. In the phase 3 DRIVE-FORWARD trial, after 48 weeks of treatment, a better lipid profile was observed in adults naive treated with two NRTIs and DOR than darunavir/ritonavir [97]. In comparison to efavirenz/emtricitabine/TDF, DOR in combination with lamivudine and tenofovir disoproxil fumarate showed minimal changes in LDL-C and non-HDL-C at week 48 in the phase 3 DRIVE-AHEAD trial [98].

In individuals with HIV suppression lasting more than six months and no history of virologic failure, the phase 3 DRIVE-SHIFT trial showed, twenty-four weeks after the switch from a stable ART to once-daily DOR/3TC/TDF, a reduction in fasting lipids that persisted until week 144 [99]. Maggi et al., in a real-life setting involving 295 subjects on RPV and 256 on DOR-based regimens, found that both regimens improved the lipid profile [100]. Doravirine was found to be more effective than rilpivirine in lowering the ratio of total cholesterol to high-density lipoprotein cholesterol. These findings suggest that doravirine may offer more benefits than rilpivirine for managing lipid levels and transaminases.

Figure 2 summarizes the interplay between HIV infection and atherosclerosis.

7. Treatment and Prevention

According to international guidelines, statins and aspirin play a critical role in reducing cardiovascular-related morbidity and mortality in PLWH, just as they do in the non-infected population (Table 1).

In a multicenter, prospective cohort study, including 1182 HIV patients, conducted to investigate the use of statins and acetylsalicylic acid (ASA) in PLWH in clinical practice, it emerged that the prescription of statins and ASA in HIV-infected patients is largely suboptimal, as only about 50% of patients requiring statins and ASA are properly treated [101].

The role of aspirin as preventive therapy is contentious. The ASPREE study found that using low-dose aspirin as the primary preventive measure for elderly subjects without HIV led to a significantly increased risk of serious bleeding but did not significantly reduce the risk of cardiovascular disease over a 5-year period when compared to a placebo [102].

The American College of Cardiology (ACC) [103] and the American Heart Association (AHA) Guidelines [104,105] on the primary prevention of cardiovascular disease recommend aspirin primarily for the secondary prevention of atherosclerotic cardiovascular disease. However, current evidence suggests that aspirin may not be beneficial for routine cardiovascular disease prevention [103].

It also indicates that adults between the ages of 50 and 59 who have a 10-year CVD risk of more than 10%, who are willing to take low-dose aspirin for at least ten years, and are not at an increased risk for bleeding, can be considered for aspirin treatment (Grade B recommendation). Individuals between the ages of 60 and 69 with a 10-year CVD risk of over 10% should consider the benefits and risks of long-term low-dose aspirin. Those most likely to benefit are without a history of bleeding, have a life expectancy of at least ten years, and are willing to use low-dose aspirin for that duration (Grade C recommendation).

Aspirin, the most widely used antiplatelet medication, may exhibit decreased therapeutic efficacy in PLWH [106].

Studies have shown that aspirin had no effect on endothelial dysfunction or immune activation indicators in a randomized clinical trial with PLWH on ART [107].

In another trial examining the effects of clopidogrel and aspirin, aspirin did not reduce platelet-induced endothelial inflammation or platelet activation [108].

The latest European AIDS Clinical Society (EACS) guidelines [109] state that, regardless of cholesterol levels, anyone with a history of vascular disease or those at high enough risk of CVD that cannot meet LDL-C goals should take statins. If a patient is at high risk due to statin intolerance, drug–drug interactions between ART and high-intensity statins, or the inability to achieve LDL-C goals while on ezetimibe and/or statins, the use of PCSK9 inhibitors and/or bempedoic acid should be considered. For very high-risk individuals (such as diabetics and post-myocardial infarction patients with another CV risk factor and triglycerides > 150 mg/dL or >1.7 mmol/L), icosapent ethyl (EPA) should be considered as an adjunct to statin therapy.

Simvastatin is contraindicated in individuals receiving treatment with protease inhibitors/ritonavir; instead, atorvastatin and rosuvastatin should be started at a low dose. This recommendation also applies to patients receiving non-nucleoside treatment. Simvastatin and lovastatin should be avoided in PLWH since they are extensively metabolized by the CYP system and can have their levels elevated by more than 500% when coadministered with CYP inhibitors [110]. Pravastatin dosages should be lowered when combined with darunavir/ritonavir.

Rosuvastatin and atorvastatin, the two highest-intensity statins, have mild interactions with ART. At their maximum commonly prescribed doses, these statins can reduce LDL-C by more than 50% [95,110]. In a randomized controlled trial, rosuvastatin 10 mg compared to placebo reduced vascular inflammation, monocyte activation indicators, and several other inflammatory markers in PLWH [111].

Pitavastatin is preferred over other statins because it has fewer negative effects on glucose metabolism, results in a higher increase in HDL-C, and has fewer drug–drug interactions [112].

Numerous studies have linked statin medication to a beneficial reduction in the common carotid artery intima–media thickness in both the general population and PLWH, encouraging the use of high-intensity statin in patients with subclinical atherosclerosis regardless of LDL-C levels or calculated 10-year risk [113].

In the REPRIEVE trial, Steven K. Grinspoon et al. randomized 7769 HIV-positive individuals taking antiretroviral medication and having a low-to-moderate risk of cardiovascular disease to receive either a placebo or daily pitavastatin calcium (at a dose of 4 mg) [114].

Participants using pitavastatin had a lower risk of major adverse cardiovascular events compared to those receiving a placebo, with a 35% reduction in risk over a median follow-up period of 5.1 years, leading to the early termination of the trial.

If a statin is not well tolerated or if the treatment target (a reduction in the percentage of LDL-C or a level of LDL-C greater than 70 mg/dL) has not been met, ezetimibe may be considered for PLWH who are at a higher risk of CVD. Saeedi et al., in a trial involving 43 PLWH, reported that after 12 weeks of treatment with either rosuvastatin 10 mg daily with ezetimibe 10 mg daily or rosuvastatin 20 mg daily alone, participants in both treatment groups showed comparable levels of LDL-C reduction. While there was no discernible change in HDL-C, the ezetimibe add-on arm showed a significant drop in TG from baseline. Finally, both treatments were well tolerated regarding side effects [115].

Given the interactions between certain ARTs and statins, PCSK9 inhibitors have emerged as a promising alternative strategy for reducing LDL-C concentrations. In a double-blind trial, Boccara et al. evaluated the safety and efficacy of evolocumab over 24 weeks in PLWH who had mixed dyslipidemia or hypercholesterolemia and were on maximally tolerated statin ttherapy [116]. Evolocumab treatment led to a reduction in LDL-C by more than 56% compared to placebo, while the placebo-corrected percentages of patients achieving an LDL-C level of <70 mg/dL and an LDL-C reduction of ≥50% were 65.4% and 71.9%, respectively. Moreover, evolocumab treatment resulted in an increase in HDL-C and a decrease in triglycerides and atherogenic lipid markers (non-HDL-C, ApoB, total cholesterol, VLDL-C, and Lp[a]). Finally, in people living with HIV, evolocumab was safe and well-tolerated.

idr-16-00066-t001_Table 1 Table 1 Treatment and prevention summary and recommendation.

Recommendation	Population	Details	Study/Source	Efficacy	
Aspirin (for prevention)	Elderly without HIV	Increased risk of serious bleeding, no significant reduction in cardiovascular disease	ASPREE study [102]	Not recommended for primary prevention	
Aspirin	Adults aged 50–59 with >10% 10-year CVD risk	Considered if willing to take for at least ten years and not at increased bleeding risk	ACC [103] and AHA Guidelines [104,105]	Grade B recommendation	
Adults aged 60–69 with >10% 10-year CVD risk	Weigh the benefits and risks; consider if there is no history of bleeding and are willing to take it for ten years	ACC and AHA Guidelines	Grade C recommendation	
Statins	PLWH with history of vascular disease or high CVD risk	Mandatory regardless of cholesterol levels; consider PCSK9 inhibitors and/or bempedoic acid if high-risk	European AIDS Clinical Society guidelines [109]	Reduces LDL-C, beneficial	
PLWH on protease inhibitors/ritonavir	Avoid simvastatin; use atorvastatin and rosuvastatin at low doses	Clinical recommendations	Avoid due to drug–drug interactions	
Ezetimibe	PLWH not meeting LDL-C treatment targets	Considered if statin is not well tolerated or LDL-C targets are not met	Clinical trial (Saeedi et al.) [115]	Comparable LDL-C reduction, well-tolerated	
PCSK9 inhibitors (Evolocumab)	PLWH on maximally tolerated statin therapy	Reduced LDL-C significantly over 24 weeks, safe and well-tolerated	Double-blind trial (Boccara et al.) [116]	Significant LDL-C reduction, safe	

8. Conclusions

The relationship between HIV infection and cardiovascular health is complex, involving patients’ risk factors and habits, the direct and indirect impacts of HIV, and the effects of ART. HIV proteins (e.g., Tat, Nef, and gp120) contribute to atherosclerosis by promoting endothelial dysfunction and inflammation. Chronic inflammation and immune activation persist even with effective viral suppression, elevating cardiovascular risks. Metabolic impairments, such as dyslipidemia and insulin resistance, are prevalent in PLWH and are exacerbated by certain ART regimens. Statins and PCSK9 inhibitors show promise in managing dyslipidemia and reducing cardiovascular events in PLWH.

However, significant gaps remain in our understanding of the precise mechanisms by which HIV infection exacerbates cardiovascular diseases. For instance, the long-term effects of chronic immune activation on the cardiovascular system are not fully understood, nor is the exact role of specific HIV proteins in accelerating atherosclerosis. Additionally, the interplay between ART-induced metabolic changes and cardiovascular risk requires further exploration, particularly in understanding how different ART regimens influence lipid profiles, insulin resistance, and vascular inflammation over time.

Future research should focus on elucidating these mechanisms, including the role of immune activation and chronic inflammation in the development of cardiovascular diseases in PLWH. Longitudinal studies are needed to assess the long-term cardiovascular outcomes of different ART regimens, considering not only their efficacy in viral suppression but also their metabolic and cardiovascular side effects. Moreover, research should investigate the potential for novel therapeutic approaches that target the specific inflammatory pathways activated by HIV, with the goal of reducing cardiovascular risk without compromising viral control.

A comprehensive, multidisciplinary approach is essential for optimizing cardiovascular care in PLWH, balancing the benefits of ART with the need to minimize cardiovascular risks. To address these issues and improve the quality of life for PLWH, ART regimens could be optimized by tailoring them to individual patient profiles, including genetic factors, comorbidities, and potential drug–drug interactions, to minimize metabolic and cardiovascular side effects. Investment in the development of newer ART drugs that have fewer cardiovascular side effects while maintaining viral suppression efficacy is also crucial.

Comprehensive cardiovascular risk management should involve routine assessments, including lipid profiles, blood pressure, and markers of inflammation, for early detection and management of cardiovascular diseases. Prevention measures for high-risk patients, such as the use of statins, PCSK9 inhibitors, and antihypertensive medications, should be encouraged. Lifestyle interventions, including a heart-healthy diet and regular physical activity, are key to managing weight, improving lipid profiles, and reducing inflammation. Additionally, resources and support for smoking cessation are essential, as smoking significantly increases cardiovascular risk in PLWH.

Clinicians should address chronic inflammation by exploring the use of anti-inflammatory drugs that have shown promise in reducing cardiovascular events in the general population. Improving gut health by restoring gut microbiota balance through probiotics, prebiotics, and dietary modifications could also reduce systemic inflammation and improve overall health.

Finally, forming multidisciplinary care teams that include infectious disease specialists, cardiologists, dietitians, and mental health professionals is crucial for providing comprehensive care tailored to the needs of PLWH. Addressing mental health issues, such as depression and anxiety, through counseling and psychiatric care is important, as these conditions can negatively impact cardiovascular health and adherence to ART. Enhancing patient education on the importance of cardiovascular health, lifestyle modifications, and adherence to treatment regimens through workshops, informational materials, and personalized counseling is also essential.

Author Contributions

Conceptualization, M.S.P.R. and A.M.; methodology, B.M.C.; investigation, S.S., C.G. and E.V.R.; writing—original draft preparation, M.S.P.R. and A.M.; writing—review and editing, A.M. and B.M.C.; supervision, B.C. and G.N. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Figure 1 HIV-mediated molecular mechanisms leading to endothelial dysfunction (created with BioRender.com).

Figure 2 Correlation between HIV and atherosclerosis/cardiovascular diseases.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Joint United Nations Programme on HIV/AIDS The Path That Ends AIDS: UNAIDS Global AIDS Update 2023 Joint United Nations Programme on HIV/AIDS Geneva, Switzerland 2023 Volume 6
2. Rodés B. Cadiñanos J. Esteban-Cantos A. Rodríguez-Centeno J. Arribas J.R. Ageing with HIV: Challenges and Biomarkers EBioMedicine 2022 77 103896 10.1016/j.ebiom.2022.103896 35228014
3. Autenrieth C.S. Beck E.J. Stelzle D. Mallouris C. Mahy M. Ghys P. Global and Regional Trends of People Living with HIV Aged 50 and over: Estimates and Projections for 2000–2020 PLoS ONE 2018 13 e0207005 10.1371/journal.pone.0207005 30496302
4. Cosentino F. Marino A. Anile L. Moscatt V. Gussio M. Boscia V. Bruno R. Nunnari G. Pulvirenti A. Privitera G.F. Long-Term Survivors in a Cohort of People Living with HIV Diagnosed between 1985 and 1994: Predictive Factors Associated with More Than 25 Years of Survival Infect Dis. Rep. 2023 15 70 83 10.3390/idr15010008 36826348
5. Celesia B.M. Marino A. Del Vecchio R.F. Bruno R. Palermo F. Gussio M. Nunnari G. Cacopardo B. Is It Safe and Cost Saving to Defer the CD4+ Cell Count Monitoring in Stable Patients on ART with More than 350 or 500 Cells/ΜL? Mediterr. J. Hematol. Infect. Dis. 2019 11 e2019063 10.4084/mjhid.2019.063 31700588
6. Marino A. Pavone G. Martorana F. Fisicaro V. Motta L. Spampinato S. Celesia B.M. Cacopardo B. Vigneri P. Nunnari G. Navigating the Nexus: HIV and Breast Cancer—A Critical Review Int. J. Mol. Sci. 2024 25 3222 10.3390/ijms25063222 38542195
7. Feinstein M.J. Hsue P.Y. Benjamin L.A. Bloomfield G.S. Currier J.S. Freiberg M.S. Grinspoon S.K. Levin J. Longenecker C.T. Post W.S. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living with HIV: A Scientific Statement from the American Heart Association Circulation 2019 140 E98 E124 10.1161/CIR.0000000000000695 31154814
8. Corti N. Menzaghi B. Orofino G. Guastavigna M. Lagi F. Di Biagio A. Taramasso L. De Socio G.V. Molteni C. Madeddu G. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study Viruses 2024 16 613 10.3390/v16040613 38675955
9. Cerrato E. Calcagno A. Ascenzo F.D. Biondi-Zoccai G. Mancone M. Marra W.G. Demarie D. Omedè P. Abbate A. Bonora S. Cardiovascular Disease in HIV Patients: From Bench to Bedside and Backwards Open Heart 2015 2 e000174 10.1136/openhrt-2014-000174 25815207
10. Eyawo O. Brockman G. Goldsmith C.H. Hull M.W. Lear S.A. Bennett M. Guillemi S. Franco-Villalobos C. Adam A. Mills E.J. Risk of Myocardial Infarction among People Living with HIV: An Updated Systematic Review and Meta-Analysis BMJ Open 2019 9 e025874 10.1136/bmjopen-2018-025874
11. Klein D.B. Leyden W.A. Xu L. Chao C.R. Horberg M.A. Towner W.J. Hurley L.B. Marcus J.L. Quesenberry C.P. Silverberg M.J. Declining Relative Risk for Myocardial Infarction Among HIV-Positive Compared With HIV-Negative Individuals With Access to Care Clin. Infect. Dis. 2015 60 1278 1280 10.1093/cid/civ014 25595743
12. Triant V.A. Lee H. Hadigan C. Grinspoon S.K. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease J. Clin. Endocrinol. Metab. 2007 92 2506 2512 10.1210/jc.2006-2190 17456578
13. Björkegren J.L.M. Lusis A.J. Atherosclerosis: Recent Developments Cell 2022 185 1630 1645 10.1016/j.cell.2022.04.004 35504280
14. Post W.S. Budoff M. Kingsley L. Palella F.J. Witt M.D. Li X. George R.T. Brown T.T. Jacobson L.P. Associations between HIV Infection and Subclinical Coronary Atherosclerosis Ann. Intern. Med. 2014 160 458 467 10.7326/M13-1754 24687069
15. Martini S. Ricci E.D. Masiello A. Zacà S. Celesia B.M. Ferrara S. Di Filippo G. Tartaglia A. Basile R. Angiletta D. Evaluation of Myo-Intimal Media Thickness and Atheromatous Plaques in People Living with HIV from the Archiprevaleat Cohort vs. HIV-Negative Subjects Biomedicines 2024 12 773 10.3390/biomedicines12040773 38672129
16. Belgrave K. Shaikh K. Budoff M.J. Risk of Peripheral Artery Disease in Human Immunodeficiency Virus Infected Individuals Ann. Transl. Med. 2018 6 S46 10.21037/atm.2018.10.08 30613621
17. Beckman J.A. Duncan M.S. Alcorn C.W. So-Armah K. Butt A.A. Goetz M.B. Tindle H.A. Sico J.J. Tracy R.P. Justice A.C. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease Circulation 2018 138 255 265 10.1161/CIRCULATIONAHA.117.032647 29535090
18. Roggero R. Robert-Hebmann V. Harrington S. Roland J. Vergne L. Jaleco S. Devaux C. Biard-Piechaczyk M. Binding of Human Immunodeficiency Virus Type 1 Gp120 to CXCR4 Induces Mitochondrial Transmembrane Depolarization and Cytochrome C-Mediated Apoptosis Independently of Fas Signaling J. Virol. 2001 75 7637 7650 10.1128/JVI.75.16.7637-7650.2001 11462036
19. Avagimyan A. Pogosova N. Kakturskiy L. Sheibani M. Urazova O. Trofimenko A. Navasardyan G. Jndoyan Z. Abgaryan K. Fogacci F. HIV-Related Atherosclerosis: State-of-the-Art-Review Curr. Probl. Cardiol. 2023 48 101783 10.1016/j.cpcardiol.2023.101783 37172874
20. Hijmans J.G. Stockelman K. Levy M. Madden Brewster L. Bammert T.D. Greiner J.J. Connick E. DeSouza C.A. Effects of HIV-1 Gp120 and TAT-Derived Microvesicles on Endothelial Cell Function J. Appl. Physiol. 2019 126 1242 1249 10.1152/japplphysiol.01048.2018 30789287
21. Madzime M. Rossouw T.M. Theron A.J. Anderson R. Steel H.C. Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets Front. Immunol. 2021 12 634386 10.3389/fimmu.2021.634386 33777022
22. Hsue P.Y. Tawakol A. Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter Circ. Cardiovasc. Imaging 2016 9 e004427 10.1161/CIRCIMAGING.116.004427 26951604
23. Feeney E.R. McAuley N. O’Halloran J.A. Rock C. Low J. Satchell C.S. Lambert J.S. Sheehan G.J. Mallon P.W.G. The Expression of Cholesterol Metabolism Genes in Monocytes from HIV-Infected Subjects Suggests Intracellular Cholesterol Accumulation J. Infect. Dis. 2013 207 628 637 10.1093/infdis/jis723 23204179
24. Wang T. Yi R. Green L.A. Chelvanambi S. Seimetz M. Clauss M. Increased Cardiovascular Disease Risk In The HIV-Positive Population on ART: Potential Role of HIV-Nef and Tat Cardiovasc. Pathol. 2015 24 279 10.1016/j.carpath.2015.07.001 26233281
25. Pushkarsky T. Shilov E. Kruglova N. Naumann R. Brichacek B. Jennelle L. Sviridov D. Kruglov A. Nedospasov S.A. Bukrinsky M. Short Communication: Accumulation of Neutral Lipids in Liver and Aorta of Nef-Transgenic Mice AIDS Res. Hum. Retroviruses 2017 33 57 60 10.1089/aid.2016.0128 27649790
26. Bernard M.A. Han X. Inderbitzin S. Agbim I. Zhao H. Koziel H. Tachado S.D. HIV-Derived SsRNA Binds to TLR8 to Induce Inflammation-Driven Macrophage Foam Cell Formation PLoS ONE 2014 9 e104039 10.1371/journal.pone.0104039 25090652
27. Fülöp T. Herbein G. Cossarizza A. Witkowski J.M. Frost E. Dupuis G. Pawelec G. Larbi A. Cellular Senescence, Immunosenescence and HIV HIV and Aging Interdisciplinary Topics in Gerontology and Geriatrics Karger International Basel, Switzerland 2016 Volume 42 10.1159/000448542
28. Marino A. Zafarana G. Ceccarelli M. Cosentino F. Moscatt V. Bruno G. Bruno R. Benanti F. Cacopardo B. Celesia B.M. Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience Diagnostics 2021 11 2336 10.3390/diagnostics11122336 34943573
29. Ghamar Talepoor A. Doroudchi M. Immunosenescence in Atherosclerosis: A Role for Chronic Viral Infections Front. Immunol. 2022 13 945016 10.3389/fimmu.2022.945016 36059478
30. Worm S.W. Hsue P. Role of Biomarkers in Predicting CVD Risk in the Setting of HIV Infection? Curr. Opin. HIV AIDS 2010 5 467 472 10.1097/COH.0b013e32833f2ea6 20978389
31. Henning R.J. Greene J.N. The Epidemiology, Mechanisms, Diagnosis and Treatment of Cardiovascular Disease in Adult Patients with HIV Am. J. Cardiovasc. Dis. 2023 13 101 37213313
32. Lembas A. Załęski A. Peller M. Mikuła T. Wiercińska-Drapało A. Human Immunodeficiency Virus as a Risk Factor for Cardiovascular Disease Cardiovasc. Toxicol. 2024 24 1 14 10.1007/s12012-023-09815-4 37982976
33. Hsue P.Y. Hunt P.W. Schnell A. Kalapus S.C. Hoh R. Ganz P. Martin J.N. Deeks S.G. Role of Viral Replication, Antiretroviral Therapy, and Immunodeficiency in HIV-Associated Atherosclerosis AIDS 2009 23 1059 1067 10.1097/QAD.0b013e32832b514b 19390417
34. Hanna D.B. Moon J.Y. Haberlen S.A. French A.L. Palella F.J. Gange S.J. Witt M.D. Kassaye S. Lazar J.M. Tien P.C. Carotid Artery Atherosclerosis Is Associated with Mortality in HIV-Positive Women and Men AIDS 2018 32 2393 2403 10.1097/QAD.0000000000001972 30102657
35. Triant V.A. Perez J. Regan S. Massaro J.M. Meigs J.B. Grinspoon S.K. D’Agostino R.B. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection Circulation 2018 137 2203 2214 10.1161/CIRCULATIONAHA.117.028975 29444987
36. Althoff K.N. Gange S.J. Klein M.B. Brooks J.T. Hogg R.S. Bosch R.J. Horberg M.A. Saag M.S. Kitahata M.M. Justice A.C. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada Clin. Infect. Dis. 2010 50 1512 1520 10.1086/652650 20415573
37. Brenchley J.M. Price D.A. Schacker T.W. Asher T.E. Silvestri G. Rao S. Kazzaz Z. Bornstein E. Lambotte O. Altmann D. Microbial Translocation Is a Cause of Systemic Immune Activation in Chronic HIV Infection Nat. Med. 2006 12 1365 1371 10.1038/nm1511 17115046
38. Tulkens J. Vergauwen G. Van Deun J. Geeurickx E. Dhondt B. Lippens L. De Scheerder M.A. Miinalainen I. Rappu P. De Geest B.G. Increased Levels of Systemic LPS-Positive Bacterial Extracellular Vesicles in Patients with Intestinal Barrier Dysfunction Gut 2020 69 191 193 10.1136/gutjnl-2018-317726 30518529
39. Vujkovic-Cvijin I. Dunham R.M. Iwai S. Maher M.C. Albright R.G. Broadhurst M.J. Hernandez R.D. Lederman M.M. Huang Y. Somsouk M. Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism Sci. Transl. Med. 2013 5 193ra91 10.1126/scitranslmed.3006438
40. Pan Z. Wu N. Jin C. Intestinal Microbiota Dysbiosis Promotes Mucosal Barrier Damage and Immune Injury in HIV-Infected Patients Can. J. Infect. Dis. Med. Microbiol. 2023 2023 3080969 10.1155/2023/3080969 37927531
41. Isnard S. Royston L. Scott S.C. Mabanga T. Lin J. Fombuena B. Bu S. Berini C.A. Goldberg M.S. Finkelman M. Translocation of Bacterial LPS Is Associated with Self-Reported Cognitive Abilities in Men Living with HIV Receiving Antiretroviral Therapy AIDS Res. Ther. 2023 20 30 10.1186/s12981-023-00525-z 37202809
42. Ouyang J. Yan J. Zhou X. Isnard S. Harypursat V. Cui H. Routy J.P. Chen Y. Relevance of Biomarkers Indicating Gut Damage and Microbial Translocation in People Living with HIV Front. Immunol. 2023 14 1173956 10.3389/fimmu.2023.1173956 37153621
43. Fragkou P.C. Moschopoulos C.D. Dimopoulou D. Triantafyllidi H. Birmpa D. Benas D. Tsiodras S. Kavatha D. Antoniadou A. Papadopoulos A. Cardiovascular Disease and Risk Assessment in People Living with HIV: Current Practices and Novel Perspectives Hell. J. Cardiol. 2023 71 42 54 10.1016/j.hjc.2022.12.013
44. Krikke M. van Lelyveld S.F.L. Tesselaar K. Arends J.E. Hoepelman I.M. Visseren F.L.J. The Role of T Cells in the Development of Cardiovascular Disease in HIV-Infected Patients Atherosclerosis 2014 237 92 98 10.1016/j.atherosclerosis.2014.08.054 25238214
45. Sarkar S. Brown T.T. Lipid Disorders in People with HIV Endotext [Internet] Feingold K.R. Anawalt B. Blackman M.R. Boyce A. Chrousos G. Corpas E. de Herder W.W. Dhatariya K. Dungan K. Hofland J. MDText.com, Inc. South Dartmouth, MA, USA 2000
46. Jung S.H. Lee K.T. Atherosclerosis by Virus Infection—A Short Review Biomedicines 2022 10 2634 10.3390/biomedicines10102634 36289895
47. Ekabe C.J. Clinton N.A. Kehbila J. Franck N.C. The Role of Inflammasome Activation in Early HIV Infection J. Immunol. Res. 2021 2021 1487287 10.1155/2021/1487287 34595244
48. Grebe A. Hoss F. Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis Circ. Res. 2018 122 1722 1740 10.1161/CIRCRESAHA.118.311362 29880500
49. Bryk D. Olejarz W. Zapolska-Downar D. Mitogen-Activated Protein Kinases in Atherosclerosis Postep. Hig. Med. Dosw. 2014 68 10 22 10.5604/17322693.1085463
50. Wu X. Liu Z. Liao W. The Involvement of Gaseous Signaling Molecules in Plant MAPK Cascades: Function and Signal Transduction Planta 2021 254 127 10.1007/s00425-021-03792-0 34812934
51. Narasimhan P. Liu J. Song Y.S. Massengale J.L. Chan P.H. VEGF Stimulates the ERK 1/2 Signaling Pathway and Apoptosis in Cerebral Endothelial Cells after Ischemic Conditions Stroke 2009 40 1467 1473 10.1161/STROKEAHA.108.534644 19228841
52. Pache L. Marsden M.D. Teriete P. Portillo A.J. Heimann D. Kim J.T. Soliman M.S.A. Dimapasoc M. Carmona C. Celeridad M. Pharmacological Activation of Non-Canonical NF-ΚB Signaling Activates Latent HIV-1 Reservoirs In Vivo Cell Rep. Med. 2020 1 100037 10.1016/j.xcrm.2020.100037 33205060
53. Avagimyan Aznauryan A. Chernova A. The Role of Viral Infection in the Mechanisms of Initiation of Atherogenesis and Destabilization of Atheroma Cardiol. Belarus 2019 11 947 953
54. Hartmann S. Jakobus C. Rengstl B. Döring C. Newrzela S. Brodt H.R. Wolf T. Hansmann M.L. Spindle-Shaped CD163+ Rosetting Macrophages Replace CD4 + T-Cells in HIV-Related Classical Hodgkin Lymphoma Mod. Pathol. 2013 26 648 657 10.1038/modpathol.2012.217 23307058
55. Sluimer J.C. Kolodgie F.D. Bijnens A.P.J.J. Maxfield K. Pacheco E. Kutys B. Duimel H. Frederik P.M. van Hinsbergh V.W.M. Virmani R. Thin-Walled Microvessels in Human Coronary Atherosclerotic Plaques Show Incomplete Endothelial Junctions. Relevance of Compromised Structural Integrity for Intraplaque Microvascular Leakage J. Am. Coll. Cardiol. 2009 53 1517 1527 10.1016/j.jacc.2008.12.056 19389562
56. Peyracchia M. De Lio G. Montrucchio C. Omedè P. d’Ettore G. Calcagno A. Vullo V. Cerrato E. Pennacchi M. Sardella G. Evaluation of Coronary Features of HIV Patients Presenting with ACS: The CUORE, a Multicenter Study Atherosclerosis 2018 274 218 226 10.1016/j.atherosclerosis.2018.05.001 29803160
57. Hsu D.C. Ma Y.F. Hur S. Li D. Rupert A. Scherzer R. Kalapus S.C. Deeks S. Sereti I. Hsue P.Y. Plasma IL-6 Levels Are Independently Associated with Atherosclerosis and Mortality in HIV-Infected Individuals on Suppressive Antiretroviral Therapy AIDS 2016 30 2065 2074 10.1097/QAD.0000000000001149 27177313
58. Subramanian S. Tawakol A. Burdo T.H. Abbara S. Wei J. Vijayakumar J. Corsini E. Abdelbaky A. Zanni M.V. Hoffmann U. Arterial Inflammation in Patients with HIV JAMA 2012 308 379 386 10.1001/jama.2012.6698 22820791
59. Lagathu C. Béréziat V. Gorwood J. Fellahi S. Bastard J.P. Vigouroux C. Boccara F. Capeau J. Metabolic Complications Affecting Adipose Tissue, Lipid and Glucose Metabolism Associated with HIV Antiretroviral Treatment Expert. Opin. Drug Saf. 2019 18 829 840 10.1080/14740338.2019.1644317 31304808
60. Masenga S.K. Elijovich F. Koethe J.R. Hamooya B.M. Heimburger D.C. Munsaka S.M. Laffer C.L. Kirabo A. Hypertension and Metabolic Syndrome in Persons with HIV Curr. Hypertens. Rep. 2020 22 78 10.1007/s11906-020-01089-3 32880756
61. Aurpibul L. Namwongprom S. Sudjaritruk T. Ounjaijean S. Metabolic Syndrome, Biochemical Markers, and Body Composition in Youth Living with Perinatal HIV Infection on Antiretroviral Treatment PLoS ONE 2020 15 e0230707 10.1371/journal.pone.0230707 32226033
62. Scherzer R. Heymsfield S.B. Lee D. Powderly W.G. Tien P.C. Bacchetti P. Shlipak M.G. Grunfeld C. Decreased Limb Muscle and Increased Central Adiposity Are Associated with 5-Year All-Cause Mortality in HIV Infection AIDS 2011 25 1405 1414 10.1097/QAD.0b013e32834884e6 21572308
63. Srinivasa S. Fitch K.V. Torriani M. Zanni M.V. Defilippi C. Christenson R. Maehler P. Looby S.E. Lo J. Grinspoon S.K. Relationship of Visceral and Subcutaneous Adipose Depots to Markers of Arterial Injury and Inflammation among Individuals with HIV AIDS 2019 33 229 236 10.1097/QAD.0000000000002060 30325779
64. Palella F.J. McKibben R. Post W.S. Li X. Budoff M. Kingsley L. Witt M.D. Jacobson L.P. Brown T.T. Anatomic Fat Depots and Coronary Plaque among Human Immunodeficiency Virus-Infected and Uninfected Men in the Multicenter AIDS Cohort Study Open Forum Infect. Dis. 2016 3 ofw098 10.1093/ofid/ofw098 27419170
65. Zicari S. Sessa L. Cotugno N. Ruggiero A. Morrocchi E. Concato C. Rocca S. Zangari P. Manno E.C. Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART Viruses 2019 11 200 10.3390/v11030200 30818749
66. Márquez M. Romero-Cores P. Montes-Oca M. Martín-Aspas A. Soto-Cárdenas M.J. Guerrero F. Fernández-Gutiérrez C. Girón-González J.A. Immune Activation Response in Chronic HIV-Infected Patients: Influence of Hepatitis C Virus Coinfection PLoS ONE 2015 10 e0119568 10.1371/journal.pone.0119568 25775475
67. Maidji E. Somsouk M. Rivera J.M. Hunt P.W. Stoddart C.A. Replication of CMV in the Gut of HIV-Infected Individuals and Epithelial Barrier Dysfunction PLoS Pathog. 2017 13 e1006202 10.1371/journal.ppat.1006202 28241080
68. Henrich T.J. Hobbs K.S. Hanhauser E. Scully E. Hogan L.E. Robles Y.P. Leadabrand K.S. Marty F.M. Palmer C.D. Jost S. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy J. Infect. Dis. 2017 216 254 262 10.1093/infdis/jix265 28838149
69. Gianella S. Anderson C.M. Var S.R. Oliveira M.F. Lada S.M. Vargas M.V. Massanella M. Little S.J. Richman D.D. Strain M.C. Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection J. Virol. 2016 90 3944 3952 10.1128/JVI.02638-15 26842469
70. Bedimo R. Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-Infected Patients Curr. HIV/AIDS Rep. 2016 13 328 339 10.1007/s11904-016-0333-9 27595755
71. Marino A. Caltabiano E. Zagami A. Onorante A. Zappalà C. Locatelli M.E. Pampaloni A. Scuderi D. Bruno R. Cacopardo B. Rapid Emergence of Cryptococcal Fungemia, Mycobacterium Chelonae Vertebral Osteomyelitis and Gastro Intestinal Stromal Tumor in a Young HIV Late Presenter: A Case Report BMC Infect. Dis. 2018 18 693 10.1186/s12879-018-3573-z 30587143
72. Maggi P. Maserati R. Antonelli G. Atherosclerosis in HIV Patients: A New Face for an Old Disease? AIDS Rev. 2006 8 204 209 17219735
73. Maggi P. Perilli F. Lillo A. Carito V. Epifani G. Bellacosa C. Pastore G. Regina G. An Ultrasound-Based Comparative Study on Carotid Plaques in HIV-Positive Patients vs. Atherosclerotic and Arteritis Patients: Atherosclerotic or Inflammatory Lesions? Coron. Artery Dis. 2007 18 23 29 10.1097/01.mca.0000236292.86930.e3 17172926
74. Soliman E. Sharma S. Arastéh K. Wohl D. Achhra A. Tambussi G. O’Connor J. Stein J. Duprez D. Neaton J. Baseline Cardiovascular Risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Trial HIV Med. 2015 16 46 54 10.1111/hiv.12233 25711323
75. Byonanebye D.M. Polizzotto M.N. Begovac J. Grabmeier-Pfistershammer K. Abela I. Castagna A. de Wit S. Mussini C. Vehreschild J.J. d’Arminio Monforte A. Incidence of Dyslipidemia in People with HIV Who Are Treated with Integrase Inhibitors versus Other Antiretroviral Agents AIDS 2021 35 869 882 10.1097/QAD.0000000000002811 33443370
76. Boccara F. Ghislain M. Meyer L. Goujard C. Le May C. Vigouroux C. Bastard J.P. Fellahi S. Capeau J. Cohen A. Impact of Protease Inhibitors on Circulating PCSK9 Levels in HIV-Infected Antiretroviral-Naive Patients from an Ongoing Prospective Cohort AIDS 2017 31 2367 2376 10.1097/QAD.0000000000001633 28857822
77. Alvi R.M. Neilan A.M. Tariq N. Awadalla M. Afshar M. Banerji D. Rokicki A. Mulligan C. Triant V.A. Zanni M.V. Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure J. Am. Coll. Cardiol. 2018 72 518 530 10.1016/j.jacc.2018.04.083 30049313
78. Bruder-Nascimento T. Kress T.C. Kennard S. Belin de Chantemèle E.J. Hiv Protease Inhibitor Ritonavir Impairs Endothelial Function via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in Nadph Oxidase 1 (Nox1), c-c Chemokine Receptor Type 5 (Ccr5), and Inflammation J. Am. Heart Assoc. 2020 9 e018074 10.1161/JAHA.120.018074 33003981
79. Ryom L. Lundgren J.D. El-Sadr W. Reiss P. Kirk O. Law M. Phillips A. Weber R. Fontas E. d’Arminio Monforte A. Cardiovascular Disease and Use of Contemporary Protease Inhibitors: The D:A:D International Prospective Multicohort Study Lancet HIV 2018 5 e291 e300 10.1016/S2352-3018(18)30043-2 29731407
80. Martini S. Pisaturo M. Russo A. Palamone M.G. Russo M.T. Zollo V. Maggi P. Coppola N. Evaluation of Lipid Profile and Intima Media Thickness in Antiretroviral-Experienced HIV-Infected Patients Treated with Protease Inhibitor-Based Regimens versus Protease Inhibitor-Sparing Regimens Pathogens 2023 12 925 10.3390/pathogens12070925 37513772
81. Hatleberg C.I. Ryom L. Sabin C. Cardiovascular Risks Associated with Protease Inhibitors for the Treatment of HIV Expert. Opin. Drug Saf. 2021 20 1351 1366 10.1080/14740338.2021.1935863 34047238
82. Pistarà E. Raddusa M.S.P. Bellocchi B. Campanella E. Moscatt V. Ceccarelli M. Celesia B.M. Management Del Paziente HIV Positivo Con Infarto Del Miocardio: Interazioni Farmacologiche e Ottimizzazione Della Terapia J. HIV Ageing 2022 7 37 40 10.19198/JHA31534
83. Molina J.M. Clotet B. van Lunzen J. Lazzarin A. Cavassini M. Henry K. Kulagin V. Givens N. de Oliveira C.F. Brennan C. Once-Daily Dolutegravir versus Darunavir plus Ritonavir for Treatment-Naive Adults with HIV-1 Infection (FLAMINGO): 96 Week Results from a Randomised, Open-Label, Phase 3b Study Lancet HIV 2015 2 e127 e136 10.1016/S2352-3018(15)00027-2 26424673
84. Deutschmann E. Bucher H.C. Jaeckel S. Gibbons S. McAllister K. Scherrer A.U. Braun D.L. Cavassini M. Hachfeld A. Calmy A. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors Clin. Infect. Dis. 2021 73 e2145 e2152 10.1093/cid/ciaa918 32634832
85. Venter W.D.F. Sokhela S. Simmons B. Moorhouse M. Fairlie L. Mashabane N. Serenata C. Akpomiemie G. Masenya M. Qavi A. Dolutegravir with Emtricitabine and Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate versus Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection (ADVANCE): Week 96 Results from a Randomised, Phase 3, Non-Inferiority Trial Lancet HIV 2020 7 e666 e676 10.1016/S2352-3018(20)30241-1 33010240
86. Bansi-Matharu L. Phillips A. Oprea C. Grabmeier-Pfistershammer K. Günthard H.F. De Wit S. Guaraldi G. Vehreschild J.J. Wit F. Law M. Contemporary Antiretrovirals and Body-Mass Index: A Prospective Study of the RESPOND Cohort Consortium Lancet HIV 2021 8 e711 e722 10.1016/S2352-3018(21)00163-6 34555326
87. O’Halloran J.A. Sahrmann J. Parra-Rodriguez L. Vo D.T. Butler A.M. Olsen M.A. Powderly W.G. Integrase Strand Transfer Inhibitors Are Associated with Incident Diabetes Mellitus in People with Human Immunodeficiency Virus Clin. Infect. Dis. 2022 75 2060 2065 10.1093/cid/ciac355 35521785
88. Byonanebye D.M. Polizzotto M.N. Neesgaard B. Sarcletti M. Matulionyte R. Braun D.L. Castagna A. de Wit S. Wit F. Fontas E. Incidence of Hypertension in People with HIV Who Are Treated with Integrase Inhibitors versus Other Antiretroviral Regimens in the RESPOND Cohort Consortium HIV Med. 2022 23 895 910 10.1111/hiv.13273 35233903
89. Taramasso L. Tatarelli P. Ricci E. Madeddu G. Menzaghi B. Squillace N. De Socio G.V. Martinelli C. Gulminetti R. Maggi P. Improvement of Lipid Profile after Switching from Efavirenz or Ritonavir-Boosted Protease Inhibitors to Rilpivirine or Once-Daily Integrase Inhibitors: Results from a Large Observational Cohort Study (SCOLTA) BMC Infect. Dis. 2018 18 357 10.1186/s12879-018-3268-5 30064371
90. Mallon P.W.G. Brunet L. Fusco J.S. Prajapati G. Beyer A. Fusco G.P. Wohlfeiler M.B. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides Open Forum Infect. Dis. 2022 9 ofab621 10.1093/ofid/ofab621 35028335
91. Lacey A. Tinago W. Power N.R. Alvarez E. Macken A.J. Sheehan G. Lambert J.S. Cotter A.G. Mallon P.W.G. Investigating the Effect of Antiretroviral Switch to Tenofovir Alafenamide on Lipid Profiles in People Living with HIV within the UCD ID Cohort J. Virus Erad. 2018 4 11 10.1016/S2055-6640(20)30376-9
92. Taramasso L. Berruti M. Briano F. Di Biagio A. The Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Determines Weight Gain in Patients on Rilpivirine-Based Regimen AIDS 2020 34 877 881 10.1097/QAD.0000000000002496 32271252
93. Sax P.E. Erlandson K.M. Lake J.E. McComsey G.A. Orkin C. Esser S. Brown T.T. Rockstroh J.K. Wei X. Carter C.C. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials Clin. Infect. Dis. 2020 71 1379 1389 10.1093/cid/ciz999 31606734
94. Huhn G.D. Shamblaw D.J. Baril J.G. Hsue P.Y. Mills B.L. Nguyen-Cleary T. McCallister S. Das M. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate Open Forum Infect. Dis. 2020 7 ofz472 10.1093/ofid/ofz472 31950070
95. Myerson M. Malvestutto C. Aberg J.A. Management of Lipid Disorders in Patients Living with HIV J. Clin. Pharmacol. 2015 55 957 974 10.1002/jcph.473 25651539
96. Rokx C. Verbon A. Rijnders B.J.A. Short Communication: Lipids and Cardiovascular Risk after Switching HIV-1 Patients on Nevirapine and Emtricitabine/Tenofovir-DF to Rilpivirine/Emtricitabine/Tenofovir-DF AIDS Res. Hum. Retroviruses 2015 31 363 367 10.1089/aid.2014.0278 25625211
97. Molina J.M. Squires K. Sax P.E. Cahn P. Lombaard J. DeJesus E. Lai M.T. Xu X. Rodgers A. Lupinacci L. Doravirine versus Ritonavir-Boosted Darunavir in Antiretroviral-Naive Adults with HIV-1 (DRIVE-FORWARD): 48-Week Results of a Randomised, Double-Blind, Phase 3, Non-Inferiority Trial Lancet HIV 2018 5 e211 e220 10.1016/S2352-3018(18)30021-3 29592840
98. Orkin C. Squires K.E. Molina J.M. Sax P.E. Wong W.W. Sussmann O. Kaplan R. Lupinacci L. Rodgers A. Xu X. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial Clin. Infect. Dis. 2019 68 535 544 10.1093/cid/ciy540 30184165
99. Kumar P. Johnson M. Molina J.M. Rizzardini G. Cahn P. Bickel M. Wan H. Xu Z.J. Morais C. Sklar P. Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression through Week 144 in the DRIVE-SHIFT Trial J. Acquir. Immune Defic. Syndr. 2021 87 801 805 10.1097/QAI.0000000000002642 33633036
100. Maggi P. Ricci E.D. Martinelli C.V. De Socio G.V. Squillace N. Molteni C. Masiello A. Orofino G. Menzaghi B. Bellagamba R. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting Viruses 2023 15 1612 10.3390/v15071612 37515298
101. De Socio G.V. Ricci E. Parruti G. Calza L. Maggi P. Celesia B.M. Orofino G. Madeddu G. Martinelli C. Menzaghi B. Statins and Aspirin Use in HIV-Infected People: Gap between European AIDS Clinical Society Guidelines and Clinical Practice: The Results from HIV-HY Study Infection 2016 44 589 597 10.1007/s15010-016-0893-z 27048184
102. McNeil J.J. Woods R.L. Nelson M.R. Reid C.M. Kirpach B. Wolfe R. Storey E. Shah R.C. Lockery J.E. Tonkin A.M. Effect of Aspirin on Disability-Free Survival in the Healthy Elderly N. Engl. J. Med. 2018 379 1499 1508 10.1056/NEJMoa1800722 30221596
103. Arnett D.K. Blumenthal R.S. Albert M.A. Buroker A.B. Goldberger Z.D. Hahn E.J. Himmelfarb C.D. Khera A. Lloyd-Jones D. McEvoy J.W. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J. Am. Coll. Cardiol. 2019 74 e177 e232 10.1016/j.jacc.2019.03.010 30894318
104. Hira R.S. Gosch K.L. Kazi D.S. Yeh R.W. Kataruka A. Maddox T.M. Shah T. Jneid H. Bhatt D.L. Virani S.S. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry Circ. Cardiovasc. Qual. Outcomes 2022 15 E007979 10.1161/CIRCOUTCOMES.121.007979 35098732
105. Cofer L.B. Barrett T.J. Berger J.S. Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach Arterioscler. Thromb. Vasc. Biol. 2022 42 1207 1216 10.1161/ATVBAHA.122.318020 36047408
106. Avgousti H. Feinstein M.J. Prevention and Treatment of Cardiovascular Disease in HIV: Practical Insights in an Evolving Field Top. Antivir. Med. 2023 31 559 565 38198667
107. O’Brien M.P. Hunt P.W. Kitch D.W. Klingman K. Stein J.H. Funderburg N.T. Berger J.S. Tebas P. Clagett B. Moisi D. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy Open Forum Infect. Dis. 2017 4 ofw278 10.1093/ofid/ofw278 28480270
108. Marcantoni E. Garshick M.S. Schwartz T. Ratnapala N. Cambria M. Dann R. O’Brien M. Heguy A. Berger J.S. Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial JACC Basic Transl. Sci. 2022 7 1086 1097 10.1016/j.jacbts.2022.06.002 36687270
109. EACS Guidelines|EACSociety Available online: https://www.eacsociety.org/guidelines/eacs-guidelines/ (accessed on 13 March 2024)
110. Feinstein M.J. Achenbach C.J. Stone N.J. Lloyd-Jones D.M. A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients Am. J. Cardiol. 2015 115 1760 1766 10.1016/j.amjcard.2015.03.025 25907504
111. Funderburg N.T. Jiang Y. Debanne S.M. Labbato D. Juchnowski S. Ferrari B. Clagett B. Robinson J. Lederman M.M. McComsey G.A. Rosuvastatin Reduces Vascular Inflammation and T-Cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy J. Acquir. Immune Defic. Syndr. 2015 68 396 404 10.1097/QAI.0000000000000478 25514794
112. Longenecker C.T. Eckard A.R. McComsey G.A. Statins to Improve Cardiovascular Outcomes in Treated HIV Infection Curr. Opin. Infect. Dis. 2016 29 1 9 10.1097/QCO.0000000000000223 26658651
113. Maggi P. De Socio G.V. Cicalini S. D’Abbraccio M. Dettorre G. Di Biagio A. Martinelli C. Nunnari G. Rusconi S. Sighinolfi L. Statins and Aspirin in the Prevention of Cardiovascular Disease among HIV-Positive Patients between Controversies and Unmet Needs: Review of the Literature and Suggestions for a Friendly Use AIDS Res. Ther. 2019 16 11 10.1186/s12981-019-0226-2 31126301
114. Grinspoon S.K. Fitch K.V. Zanni M.V. Fichtenbaum C.J. Umbleja T. Aberg J.A. Overton E.T. Malvestutto C.D. Bloomfield G.S. Currier J.S. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection N. Engl. J. Med. 2023 389 687 699 10.1056/NEJMoa2304146 37486775
115. Saeedi R. Johns K. Frohlich J. Bennett M.T. Bondy G. Lipid Lowering Efficacy and Safety of Ezetimibe Combined with Rosuvastatin Compared with Titrating Rosuvastatin Monotherapy in HIV-Positive Patients Lipids Health Dis. 2015 14 57 10.1186/s12944-015-0054-x 26087958
116. Boccara F. Kumar P.N. Caramelli B. Calmy A. López J.A.G. Bray S. Cyrille M. Rosenson R.S. Baker D. Bloch M. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study J. Am. Coll. Cardiol. 2020 75 2570 2584 10.1016/j.jacc.2020.03.025 32234462
